Agnes Kohl, Mpharmsc
Head of Business Development
Head of Business Development
AOP FOCUS ON RARE DISEASE
Russian Federation
Biography
A major part of its commercial success is based on business development for in-licensed products. Half of the company’s annual revenue is attributable to this segment. AOP Orphan has opened the door to key markets for companies such as United Therapeutics, Cardiome, Aegerion and Ferrer. On the other hand, medicinal products developed by AOP Orphan could also be marketed through partners in other promising regions such as South America, Canada or Northern Europe.
Research Interest
A major part of its commercial success is based on business development for in-licensed products. Half of the company’s annual revenue is attributable to this segment. AOP Orphan has opened the door to key markets for companies such as United Therapeutics, Cardiome, Aegerion and Ferrer. On the other hand, medicinal products developed by AOP Orphan could also be marketed through partners in other promising regions such as South America, Canada or Northern Europe.
